# GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

> **NCT00044343** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 80 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00044343
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2014-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044343, "GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00044343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*